uniQure (NasdaqGS:QURE) has drawn fresh attention after recent trading, with the stock closing at US$28.22 and sitting on a market cap of about US$1.80b. This has prompted investors to reassess its gene therapy pipeline.

Recent trading has been volatile, with a 16.66% 7 day share price return and a 47.52% 30 day share price return building on a very strong 212.51% 90 day share price return. The 1 year total shareholder return of 94.82% reflects compounding gains over a longer period.

If rapid moves in uniQure have you looking wider across healthcare, this is a good moment to scan for other potential biotech ideas in 40 healthcare AI stocks

With revenue of US$18.09m, a reported net loss of US$208.87m and a stock trading at US$28.22 compared with an analyst price target near US$39.05, should you see value here or consider that the market is already pricing in future growth?

Most Popular Narrative: 27.7% Undervalued

At a last close of $28.22 versus a narrative fair value of $39.05, the market price sits well below what the most followed storyline implies.

The potential accelerated approval for AMT-130 in treating Huntington's disease could significantly boost future revenues as it would be one of the first disease-modifying treatments available for this condition. Expansion of the clinical pipeline with new studies in refractory temporal lobe epilepsy, Fabry disease, and SOD1-ALS could lead to additional revenue streams if these treatments are successful and commercialized.

Analysts are tying a high growth runway, rising profit margins and a steep future earnings multiple into one story. Curious which assumptions have to line up for that $39.05 figure to make sense?

Result: Fair Value of $39.05 (UNDERVALUED)

However, there is still real risk that stricter FDA trial expectations for AMT-130 and reliance on external manufacturing could undercut the bullish fair value story.

Next Steps

With sentiment clearly split between opportunity and risk, this is a good moment to move quickly. Check the underlying data yourself and weigh the 1 key reward and 4 important warning signs in 1 key reward and 4 important warning signs.

Looking for more investment ideas?

If uniQure has caught your attention, do not stop here. Use this momentum to broaden your watchlist and uncover other stocks that could fit your goals.

• Spot potential turnaround opportunities early by checking out 24 elite penny stocks with strong financials.
• Zero in on companies that combine quality with appealing prices through 47 high quality undervalued stocks.
• Focus on resilient businesses backed by strong finances using the solid balance sheet and fundamentals stocks screener (45 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.